Retail Clinics

CINCINNATI — Kroger is highlighting immunization against the flu this season on the company's website.

NEWTOWN SQUARE, Pa. — Nearly 39 million people, or 12.5% of the U.S. population, are feeling the effects of cold and flu as high illness levels continued across the nation, Boiron stated Friday, citing SDI Health data.

Some of the most prevalent indications are fever and influenza-like symptoms, such as chills, body aches and headache.

WASHINGTON — Life…supplemented on Thursday announced its fundraising initiative, “Why You Want to Be Well,” for Vitamin Angels for March, and will use Facebook to raise up to $5,000.

NEW YORK — The Spaniards drink Rioja wine with a hearty “Salud!,” while the Irish knock back Jameson whiskey and Guinness beer with “Slainte.” Nobody can say who coined the two calls to imbibe, both of which mean “health,” but according to two recent studies, it looks as though they were on to something.

ANN ARBOR, Mich. — A convenient blood-glucose test commonly used to diagnose diabetes and prediabetes may not be the best way to diagnose children, according to a new study.

MONROVIA, Calif. — Biotab Nutraceuticals on Tuesday initiated a voluntary recall of two lots of Extenze nutritional supplement tablets.

Some packages bearing lot numbers 0709241 and 0509075 are counterfeit products containing undeclared drug ingredients that can pose a serious risk to health, the company stated.

MOUNTAIN VIEW, Calif. — LifeScience Plus recently introduced Advanced BloodStop, a bandage that helps stop bleeding in less than one minute, at CVS/pharmacy.

“We are very excited to be able to offer this product through CVS,” stated Wayne Korteweg, COO of LifeScience Plus. “BloodStop is so much more effective and versatile than ordinary bandages; it’s an essential for any medicine cabinet, first aid kit or car for home or travel emergencies.”

PRINCETON, N.J., and WILMINGTON, Del. — The makers behind a popular Type 2 diabetes treatment have included data from two clinical studies in an update to the drug's prescribing information.

Bristol-Myers Squibb and AstraZeneca said the Food and Drug Administration approved the labeling update for Onglyza (saxagliptin), which now includes efficacy and safety information about the drug's effects on patients with renal impairment or end-stage renal disease.